Protective Effect of Type 2 Diabetes on Acetaminophen-Induced Hepatotoxicity in Male Swiss-Webster Mice

Sharmilee P. Sawant, Ankur V. Dnyanmote, Mayurrjanan S. Mitra, Jaya Chilakapati, Alan Warbritton, John R. Latendresse, and Harihara M. Mehendale

Department of Toxicology, College of Pharmacy, University of Louisiana at Monroe, Monroe, Louisiana (S.P.S., A.V.D., M.S.M., J.C., H.M.M.); and Toxicologic Pathology Associates, National Center for Toxicological Research, Jefferson, Arkansas (A.W., J.R.L.)

Received August 17, 2005; accepted October 4, 2005

ABSTRACT

Type 2 diabetic (DB) mice exposed to CCl4 (LD50 = 1.25 ml/kg), acetaminophen (LD50 = 600 mg/kg; APAP), and bromobenzene (LD50 = 0.5 ml/kg) i.p. yielded 30, 20, and 20% mortality, respectively, indicating hepatotoxic resistance. Male Swiss-Webster mice were made diabetic by feeding high fat and administrating streptozotocin (120 mg/kg i.p.) on day 60. On day 71, time-course studies after APAP (600 mg/kg) treatment revealed identical initial liver injury in non-DB and DB mice, which progressed only in non-DB mice, resulting in 80% mortality. The hypothesis that decreased APAP bioactivation, altered toxicokinetics, and/or increased tissue repair are the underlying mechanisms was investigated. High-performance liquid chromatography analysis revealed no difference in plasma and urinary APAP or detoxification of APAP via glucuronidation between DB and non-DB mice. Hepatic CYP2E1 protein and activity, glutathione, and [14C]APAP covalent binding did not differ between DB and non-DB mice, suggesting that lower bioactivation-based injury is not the mechanism of decreased hepatotoxicity in DB mice. Diabetes increased cells in S phase by 8-fold in normally quiescent liver of these mice. Immunohistochemistry revealed overexpression of calpastatin in the newly dividing/divided cells, explaining inhibition of hydrolytic enzyme calpain in perinecrotic areas and lower progression of APAP-initiated injury in the DB mice. Antimitotic intervention of diabetes-associated cell division with colchicine before APAP administration resulted in 70% mortality in APAP-treated colchicine-intervened DB mice. These studies suggest that advancement of cells in the cell division cycle and higher tissue repair protect DB mice by preventing progression of APAP-initiated liver injury that normally leads to mortality.

An epidemiological study showed that diabetic (DB) patients are nearly twice as likely to suffer from hepatic failure compared with non-DB patients (El-Serag and Everhart, 2002). Several studies conducted in type 1 DB rats and mice to test hepatotoxic sensitivity clearly indicate that type 1 DB rats are sensitive (El-Hawari and Plaa, 1983; Grant and Duthie, 1988; Watkins et al., 1988; Wang et al., 2000a), whereas the type 1 DB mice are resistant to hepatotoxicity induced by several dissimilar hepatotoxicants (Shankar et al., 2003a,c), indicating species difference in hepatotoxic sensitivity. Studies by Wang et al. (2000a,b, 2001) in type 1 DB rats indicated that inhibited compensatory tissue repair plays a determining role in the final toxic outcome after thioacetamide (TA) administration. In stark contrast, type 1 DB mice challenged with TA and acetaminophen (APAP) exhibit higher hepatic tissue repair (Shankar et al., 2003a) and higher renal tissue repair after challenge with 1,2-dichlorovinyl-L-cysteine (Dnyanmote et al., 2005). It is known that hepatoprotection in type 1 DB mice is dependent on PPAR-α activation (Shankar et al., 2003b).

Very few studies have investigated the effect of type 2 diabetes on hepatotoxic sensitivity, even though it is the most prevalent form of diabetes, representing 90 to 95% of the DB patients. One reason is the lack of a robust and well characterized type 2 DB rodent model. Disadvantages of most commonly used genetic models are transient and moderate hyperglycemia (3–5 months of age), lack of insulin resistance, and higher renal tissue repair after challenge with 1,2-dichlorovinyl-L-cysteine (Dnyanmote et al., 2005). It is known that hepatoprotection in type 1 DB mice is dependent on PPAR-α activation (Shankar et al., 2003b). This study was supported by The Louisiana Board of Regents Fund through University of Louisiana at Monroe, Kitty DeGree Chair in Pharmacy (Toxicology).

S.P.S. is a recipient of predoctoral fellowship award from American Heart Association, Southern Affiliate.

Article, publication date, and citation information can be found at http://jpet.aspetjournals.org. doi:10.1124/jpet.105.094326.

ABBREVIATIONS: DB, diabetic; non-DB, nondiabetic; TA, thioacetamide; APAP, acetaminophen; PPAR, peroxisome proliferator-activated receptor; GSH, glutathione; BB, bromobenzene; CLC, colchicine; SW, Swiss-Webster; [3H]T, [3H-CH3]thymidine; STZ, streptozotocin; HFD, high fat diet; ND, normal diet; ALT, alanine aminotransferase; AST, aspartate aminotransferase; PCNA, proliferating cell nuclear antigen; HRP, horseradish peroxidase; TCA, trichloroacetic acid; APAP-G, acetaminophen glucuronide; HPLC, high-performance liquid chromatography; DAB, diaminobenzidine; H&E, hematoxylin and eosin; DW, distilled water.
and extreme degree of hyperinsulinemia (Bailey and Flatt, 1991; Portha et al., 1991). Recently, Sawant et al. (2004) have refined and characterized a nonobese type 2 diabetes rat model based on high fat diet and a low dose of streptozotocin. Using 10 different parameters, Sawant et al. (2004) reported that these DB rats closely resemble type 2 DB patients. Their studies revealed for the first time that type 2 DB rats are sensitive to structurally and mechanistically different hepatotoxicants (Sawant et al., 2004), similar to type 1 DB rats. Time-course studies using two-model hepatotoxicants, CCl₄ and TA, showed that CCl₄ and TA hepatotoxicity is potentiated in type 2 DB rats not because of increased bioactivation-based mechanisms but because of inhibited compensatory tissue repair response (Sawant et al., 2004, 2005).

Whether there is species difference in hepatotoxic sensitivity due to type 2 diabetes similar to that observed in type 1 DB rats and mice is not known. Therefore, the objectives of the present study were to evaluate hepatotoxic sensitivity of type 2 DB mice to three dissimilar hepatotoxicants, including APAP and to investigate the mechanisms of hepatotoxic resistance.

APAP remains the most common cause of acute liver failure in the United States and other parts of the world as a result of accidental or deliberate overdose (Dargan and Jones, 2003). Several mechanisms have been shown to protect from APAP hepatotoxicity such as inhibition of cytochromes P450 (Mitchell et al., 1973; Zaher et al., 1998); enhanced detoxification via glucuronidation of APAP (Hazelton et al., 1986); treatment with N-acetylcysteine, repletion of glutathione (GSH), or enhanced antioxidant status (Corcoran et al., 1985; Jaeschke, 1990); inhibition of hydrolytic enzymes, such as calpain by treatment with synthetic calpain inhibitor or overexpression of endogenous inhibitor calpastatin (Limaye et al., 2003, 2005); and stimulated cell division and liver tissue repair (Shankar et al., 2003a,b).

Using APAP, CCl₄, and bromobenzene (BB) as model hepatotoxicants, we tested the hypothesis that type 2 DB mice exhibit hepatotoxic resistance. The specific aims of the present study were to investigate whether protection from APAP-induced hepatotoxicity in the DB mice is due to 1) decreased bioactivation via decreased CYP2E1 and decreased covalent binding of [14C]APAP-derived radiolabel to liver macromolecules; 2) increased detoxification via nontoxic APAP glucuronidation and glutathione conjugation; 3) advancement of liver cells to S phase in type 2 DB mice, unlike in the quiescent non-DB mice, thereby protecting DB mice from expansion of APAP-initiated liver injury; and 4) overexpression of calpastatin in dividing or newly divided cells, resulting in decreased progression of liver injury via inhibited calpain after exposure to APAP. Finally, to test whether or not diabetes-related advancement of liver cells to S phase is critical for hepatoprotection, DB mice received colchicine (CLC) intervention before the administration of APAP.

Here we report that, unlike the type 2 DB rats, the type 2 DB mice are resistant to three dissimilar hepatotoxicants. The resistance of type 2 DB mice against APAP hepatotoxicity seems to be neither because of decreased bioactivation nor because of altered toxicokinetics but because of diabetes-associated 8-fold advancement of hepatocytes to S phase, which prevents progression of APAP-initiated injury while facilitating restoration of liver structure and function via early onset of robust tissue repair. Inhibition of this entry into S phase of cell division by CLC intervention abolished the hepatoprotection in the DB mice, which lends further credence to the notion that diabetes-related advancement of cells in cell division cycle and higher tissue repair are pivotal to the protection of type 2 DB mice from APAP hepatotoxicity.

Materials and Methods

Animals and Diets

Male Swiss-Webster (SW) mice (25–30 g) were obtained from Harlan (Indianapolis, IN). They were housed over sawdust bedding (Sani-Chips; Harlan Teklad, Madison, WI) in a controlled environment (temperature 21 ± 1°C, humidity 50 ± 10%, and 12:12-h light/dark cycle) and were acclimatized for a week before use in experiments. Mice had free access to water and rodent chow (normal rodent diet consisting of 6% fat, 20% protein, and 46% carbohydrate (Dyets no. 100795; Dyets Inc., Bethlehem, PA)). Animal maintenance and treatment were in accordance with the National Institute of Health Guide for Laboratory Animal Welfare, as approved by our Institutional Animal Care and Use Committee.

Chemicals

Unless stated otherwise, all chemicals and biochemical kits were purchased from Sigma-Aldrich (St. Louis, MO) and Thermo Electron Corporation (Waltham, MA), respectively. [3H-CH₃]Thymidine ([3H]T, 2 Ci/mmol) was purchased from Moravek Biochemicals (Brea, CA). Scintillation fluid was obtained from Fisher Scientific Co. ( Baton Rouge, LA).

Treatments

Induction of Type 2 Diabetes. The experimental protocol described previously (Sawant et al., 2004) to induce type 2 diabetes in rats was used to induce diabetes in mice. Preliminary studies established that induction of type 2 diabetes in mice required longer duration of feeding high fat diet. SW mice were fed high fat diet for 60 days, unlike the 2-week protocol for Sprague-Dawley rats. Beginning on day 0, mice were fed either normal rodent chow or high fat diet. On day 60, mice on the high fat diet were injected with either a single dose of streptozotocin (STZ, 120 mg/kg i.p. in 0.01 M citrate buffer, pH 4.3, HFD + STZ) to induce diabetes or citrate buffer (10 ml/kg i.p.) (HFD) to serve as vehicle control. Mice on the normal rodent diet injected with either a single dose of STZ (120 mg/kg i.p. in 0.01 M citrate buffer, pH 4.3) (ND + STZ) or citrate buffer (10 ml/kg i.p.) (ND) served as non-DB controls. Subsequent to STZ or citrate buffer treatment, mice had free access to food and water and were continued on their respective diets for the entire duration of study. Blood sampled from the retro-orbital plexus under diethyl ether anesthesia on day 70 was used to measure plasma glucose and insulin concentrations. Mice exhibiting plasma glucose (400 ± 54 mg/dl) compared with the non-DB mice (ND, ND + STZ, and HFD; 128 ± 10 mg/dl) (kit 315-100; Sigma-Aldrich) and plasma insulin in the normal range of 0.5 to 2 ng/ml (enzyme-linked immunosorbent assay; Crystal Chemical Inc., Downers Grove, IL) were considered to have type 2 diabetes (HFD + STZ). Thus, the HFD + STZ group represents the DB group. The three non-DB controls were ND, ND + STZ, and HFD. This protocol routinely renders 90% of the mice maintained on high fat diet and given STZ diabetic.

Characterization of Type 2 Diabetes Model

Glucose and Insulin Levels. On day 70 of the experimental protocol, in the DB mice (HFD + STZ), type 2 diabetes was confirmed by measuring nonfasting plasma glucose and plasma insulin levels.
Oral Glucose Tolerance Test. To assess oral glucose tolerance, mice \( (n = 4 \text{ in each group}) \) were fasted overnight (12 h), and their plasma glucose response to oral administration of a bolus glucose solution (20% solution; 5 g/kg) was determined. Blood samples were taken from the retro-orbital plexus under diethyl ether anesthesia before (time 0) and 2 h after glucose administration. Plasma glucose and insulin concentrations were estimated.

Lethality Study. On day 71 of the experimental protocol, DB (HFD + STZ) and non-DB mice (ND, ND + STZ, and HFD) \( (n = 10 \text{/group}) \) were treated with CCl\(_4\) (1.25 ml/kg i.p. in 10 ml of corn oil/kg) or corn oil (10 ml/kg i.p.); APAP (600 mg/kg i.p. in 20 ml of warm basic saline/kg, pH 8) or vehicle control (warm basic saline, pH 8; 20 ml/kg); or BB (0.5 ml/kg i.p. in 10 ml of corn oil or corn oil (10 ml/kg i.p.). Survival and mortality were recorded three times on the first day and twice daily thereafter for a total of 14 days.

APAP-Induced Liver Injury. On day 71, DB (HFD + STZ) and non-DB mice (ND, HFD, and ND + STZ) were treated with either a single injection of APAP (600 mg/kg i.p. in warm basic saline, pH 8; 20 ml/kg) or vehicle control (20 ml/kg i.p. in warm basic saline, pH 8). The mice treated with APAP were terminated with diethyl ether either for the time-course studies (0–96 h). Four mice \( (n = 4) \) were treated per group per time point, except for non-DB groups \( (n = 20) \) treated for APAP, to obtain four surviving mice at 12, 24, 48, and 96 h after APAP administration.

The plasma and liver tissue from these mice were collected at 0, 6, 12, 24, 48, and 96 h after dosing. From the DB and non-DB mice treated with warm basic saline vehicle, blood and liver samples were collected only at 0, 12, and 24 h after saline administration \( (n = 4/i.p./group/time \text{point}) \).

Hepatotoxicity. Estimation of Liver Injury. Plasma alanine aminotransferase (ALT) and aspartate aminotransferase (AST) were measured as biomarkers of liver injury using kit TR 7111-125 and kit TR 7011-125, respectively (Thermo Electron Corporation).

Histopathology. Portions of liver were taken from the left lateral lobes and fixed immediately in 10% phosphate-buffered formalin and after 48 h stored in 70% alcohol until further processing. The liver sections were processed and then embedded in paraffin. Liver sections were prepared for calpain, calpastatin, and proliferation (H&E) for histological examination by light microscopy. Unstained quantitation using Quantity One software (Bio-Rad). To detect CYP2E1 protein, nitrocellulose membranes (Bio-Rad) were washed eight times with 80% methanol (6 ml/wash), and the radioactivity in the methanol wash was estimated each time. After eight methanol washings, no radioactivity was detected in the supernatant. The pellets (containing covalently bound \(^{14}C\)APAP-derived radiolabel) were air-dried, dissolved in 2 ml of 1 N NaOH, and an aliquot was used to estimate \(^{14}C\)APAP using a liquid scintillation counter. The protein concentrations were determined using a Bio-Rad protein assay kit (Bio-Rad).

Effect of Type 2 Diabetes on Hepatic Microsomal CYP2E1 and Covalent Binding to Liver Macromolecules.

Preparation of Microsomes. Liver microsomes were prepared by differential ultracentrifugation using the method described previously (Chippman et al., 1979). Protein content of the microsomes was estimated by the Bradford method using the Bio-Rad protein assay kit (Bio-Rad). The results are expressed as dpm per milligram of liver protein.

CYP2E1 Enzyme Activity Assays. Microsomal CYP2E1-dependent hydroxylation of \( \mathrm{p} \)-nitrophenol to \( \mathrm{p} \)-nitrophenol was used as a standard assay to quantify CYP2E1 activity (Wang et al., 2001).

In Vivo Covalent Binding of \(^{14}C\)APAP-Derived Radiolabel to Liver Proteins. Covalent binding of \(^{14}C\)APAP-derived radiolabel to liver macromolecules was estimated using procedure described by Shankar et al. (2003a). In brief, liver tissue (200 mg) was homogenized in 1 ml of 0.9% saline, and total protein was precipitated using 2 ml of 0.9 M trichloroacetic acid (TCA). Samples were centrifuged at 1000 g for 15 min at room temperature. The supernatant was discarded, and the precipitate was resuspended in 3 ml of 0.6 M TCA, mixed using a Vortex agitator, and centrifuged at 1000 g for 5 min. After two more washings with 0.6 M TCA, the pellet was washed eight times with 80% methanol (6 ml/wash), and the radioactivity in the methanol wash was estimated each time. After eight methanol washings, no radioactivity was detected in the supernatant. The pellets (containing covalently bound \(^{14}C\)APAP-derived radiolabel) were air-dried, dissolved in 2 ml of 1 N NaOH, and an aliquot was used to estimate \(^{14}C\)APAP using a liquid scintillation counter. The protein concentrations were determined using a Bio-Rad protein assay kit (Bio-Rad). The results are expressed as dpm per milligram of liver protein.

Effect of Type 2 Diabetes on APAP Toxicokinetics.

Toxicokinetic Parameters of APAP. Blood \( (50 \mu l) \) was collected from non-DB (ND) and DB mice at 0, 5, 10, 15, 30, 45, 60, 120, 180, 240, 360, and 720 min after APAP administration (600 mg/kg i.p.). To complete the entire time course once \( (n = 1) \), three mice had to be used. Four time points were collected from each mouse over-lapping one time point between mice. Three such replicate time courses \( (n = 3) \) were performed for ND and DB mice. APAP and APAP-glucuronide (APAP-G) were estimated using a reverse-phase HPLC analysis using a SPS-ODS column \((5 \mu m; \text{Regis Technologies, Mttorongue, IL})\). In a separate study \( (n = 45 \text{ and } 12 \text{ for ND and DB mice, respectively}) \), urine was collected at 0, 12, and 24 h after APAP administration to ND and DB mice. For the estimation of plasma APAP and APAP-G and urinary APAP levels, 7% acetonitrile in Na\(^{-}\)K\(^{-}\)-phosphate \((50 \text{ mM})\) buffer, pH 7.4, was used as the mobile phase at a flow rate of 1 ml/min (Shankar et al., 2003a).

However, for the estimation of the urinary APAP-G, the urine samples were diluted with two volumes of ice-cold methanol (HPLC grade, Sigma-Aldrich) and centrifuged at 1200 g for 30 min, 100 \( \mu l \) of the supernatant was used for HPLC analysis. The urinary APAP-G was estimated by HPLC analysis using an isocratic mobile phase of 12.5% methanol, 1% acetic acid, and 86.5% deionized water at a flow rate of 0.8 ml/min (Chen et al., 2005) using a reverse-phase column (SPS-ODS column, 5 \( \mu m; \text{Regis Technologies} \)).

APAP and APAP-G (HPLC grade; Sigma-Aldrich) were used as standards. APAP-G and APAP were detected at 254 nm, with retention times of 2.6 and 8.1 min, respectively, using a PDA-100 photodiode array detector (Dionex Systems, Sunnyvale, CA). Plasma half-life \( (t_{1/2}) \) for APAP was computed using the elimination constant \((\beta)\), where \( t_{1/2} = 0.693/\beta \). The value of \( \beta \) was estimated using a semilogarithmic plot of time versus concentration (up to 360 min) using JMP-IN statistical software (SAS Institute, Inc., Cary, NC).

Glutathione Estimation. Total and reduced GSH was estimated in livers of non-DB (ND) and DB mice challenged with APAP \((600 \text{ mg/kg i.p.}) \) at 0, 2, and 6 h after APAP treatment. A commercially available kit (catalog no. 703002) from Cayman Chemical (Ann Arbor, MI) was used. The kit is based on enzymatic recycling of GSH using GSH reductase followed by reaction of GSH with Ellman’s reagent. Blue-colored product was read at 405 nm and quantitated on a standard curve.
Progression and Regression of Injury: Calpain-Calpastatin System

Calpain and Calpastatin Immunohistochemistry. Calpain immunohistochemistry was conducted using a method described previously (Limaye et al., 2003). In brief, liver sections from the non-DB (ND) and DB mice were deparaffinized and antigen retrieval was achieved using citrate buffer, pH 6.0, for 8 min. The sections were blocked using 3% bovine serum albumin for 1 h and incubated with polyclonal anti-rabbit primary calpastatin antibody (1:300; Sigma-Aldrich) for 14 h at 4°C. An HRP-conjugated secondary anti-rabbit IgG antibody (1:500) was then linked to the primary antibody before incubation with diaminobenzidine (DAB), which gives a brown reaction product. The cells were counterstained with hematoxylin, dehydrated, and observed for localization of calpain.

The protocol followed for calpastatin immunohistochemistry was similar to that followed for calpain. In brief, liver sections from the non-DB (ND) and DB mice were deparaffinized and were blocked using 3% bovine serum albumin for 1 h and incubated with polyclonal anti-rabbit primary calpastatin antibody (1:300; Sigma-Aldrich) for 14 h at 4°C. An HRP-conjugated secondary anti-rabbit IgG antibody (1:500) was then linked to the primary antibody before incubation with DAB, which gives a brown reaction product. The cells were counterstained with hematoxylin, dehydrated, and observed for localization of calpastatin.

Tissue Repair

\[^{3}H\text{IT} \text{ Incorporation.}\] S phase DNA synthesis was measured by \[^{3}H\text{IT} \text{ incorporation into hepatoneural DNA as described previously (Sawant et al., 2004)}\] in the DB and non-DB mice before APAP treatment to investigate whether type 2 diabetes alters S phase DNA synthesis.

Proliferating Cell Nuclear Antigen Assay. Cell-cycle progression was estimated by immunohistochemical analysis with PCNA labeled with the brown reaction product of DAB and HRP (Greenwell et al., 1991). Nuclei were counterstained lightly with hematoxylin. Observed under light microscopy, nuclei of G0 cells were blue; cells in G1 were stippled light brown, S phase cell nuclei were stained dark brown, whereas G2 cells had stippled light brown cytoplasmic staining with brown speckled nuclear appearance, and M cells had diffuse light brown cytoplasmic and deep blue chromosomal staining. For histomorphometric analysis, each section was observed for cells in different stages of the cell cycle in 10 high-power fields (400× magnification) as reported previously (Wang et al., 2000a). One thousand cells per slide were counted, and the number of cells (percentage) in each stage was recorded.

CYP4A Western Blot Analysis. Liver microsomal protein (20 μg) from each mouse was separated by SDS-polyacrylamide gel electrophoresis and transferred to membranes (Wang et al., 2001). To detect CYP4A protein, nitrocellulose membranes (Bio-Rad) were incubated with a primary goat anti-rat CYP4A polyclonal antibody (1:2,000; Sigma-Aldrich) for 14 h at 4°C. An HRP-conjugated secondary anti-rabbit IgG antibody (1:500) was then linked to the primary antibody before incubation with DAB, which gives a brown reaction product. The cells were counterstained with hematoxylin, dehydrated, and observed for localization of CYP4A.

CLC Antimitotic Intervention

Treatment, Lethality, and Time-Course Studies after CLC Intervention. Intervenional studies with CLC were conducted to test the role of diabetes-related advancement of cells to S phase and higher tissue repair in the type 2 DB mice. CLC is known to exert antimitosis by a combination of inhibition of DNA synthesis as indicated by decreased \[^{3}H\text{IT} \text{ incorporation by inhibition of thymidine kinase and thymidylate synthetase (Tsukamoto and Kojo, 1989)}\] and microtubule perturbations (Manfredi and Horwitz, 1984).

On day 68 of the experimental protocol, type 2 diabetes was confirmed by measuring plasma glucose and insulin levels. On days 69 and 70, one group of DB mice (n = 10/group) received CLC (2 and 1.5 mg/kg i.p. in distilled water at 48 and 12 h before APAP administration, respectively), whereas the other group received distilled water (10 ml/kg i.p. vehicle control for CLC at 48 and 12 h before APAP administration), respectively. On day 71, both the groups of DB mice received APAP (600 mg/kg i.p. in warm basic saline, pH 8). Another group of non-DB mice (ND) treated with CLC (2 and 1.5 ml/kg i.p. on days 69 and 70, respectively) received saline (20 ml/kg i.p.) and served as controls to test any effects of CLC itself. Mice were observed thrice for the first day and then twice daily for a total of 14 days, and survival and mortality were recorded. For the time-course (0–24 h) study, liver injury as measured by plasma ALT and AST was estimated in the non-DB (ND only), CLC-intervened DB mice (DB + CLC), and CLC-unintervened DB mice pretreated with DW (DB + DW).

After confirming type 2 diabetes, one group of DB mice (DB + CLC; n = 4/time point for 0 and 6 h and n = 15/time point for 12 and 24 h) was treated with two doses of CLC (2 mg/kg i.p. in distilled water at 48 h and 1.5 mg/kg i.p. in distilled water at 12 h, respectively) before APAP treatment. The other group of DB mice (DB + DW) received distilled water (10 ml/kg i.p.; n = 4/time point) and served as vehicle control. Both the DB groups (DB + CLC and DB + DW) were treated with APAP on day 71. A non-DB (ND) group (pretreated with vehicle of CLC (DW, 10 ml/kg i.p.)) treated with APAP for the time-course study was also maintained. The plasma and liver tissue from these mice were collected at 0, 6, 12, and 24 h after dosing with APAP (DB + CLC, DB + DW, and ND + DW). Plasma ALT and AST were measured as biomarkers of liver injury using kit TR 7111-125 and kit TR 7011-125, respectively (Thermo Electron Corporation).

In Vivo Covalent Binding of \(^{14}C\text{APAP-Derived Radiolabel to Liver Proteins after CLC Intervention.}\] Covalent binding of \(^{14}C\text{APAP-derived radiolabel to liver macromolecules was estimated in the non-DB mice (ND only) and DB mice with and without CLC pretreatment. Livers from ND mice and DB mice with and without CLC intervention and treated with \(^{14}C\text{APAP (600 mg/kg i.p.; 4.3 mCi/mmol; 5 μCi/mouse; Sigma-Aldrich)}\] were flash-frozen at 2 h after APAP treatment. Covalently bound \(^{14}C\text{APAP-derived label to liver macromolecules was estimated using the procedure described above. Results were expressed as dpm per milligram of liver protein.}\]

Statistical Analysis

Data are expressed as means ± S.E. Comparison was made by Student’s t test. Comparison between different time points for each group and between two groups at the same time point was made by analysis of variance followed by Tukey’s honestly significant difference test using the factorial design and the JMP software (SAS Institute Inc.). The criterion for significance was p ≤ 0.05.

Results

Characterization of Type 2 Diabetes Mouse Model

All of the DB mice survived, and they seemed healthy. They exhibited weight loss but without any significant change in liver-to-body weight ratio, significantly higher water and food intake, and 10-fold higher urine output (70 ± 9 ml/day) compared with the non-DB mice (7 ± 1 ml/day).

On day 70, type 2 DB mice showed significant elevation in plasma glucose (128 ± 10 mg/dl in the non-DB mice (ND) compared with 400 ± 54 mg/dl in the DB mice) and insulin levels in the normal range [1.9 ± 0.1 in non-DB (ND) mice compared with 1.7 ± 0.5 in DB mice]. The ND + STZ mice exhibited normal glucose and insulin levels; however, the high fat diet fed mice exhibited 1.5-fold higher insulin levels and normal glucose levels compared with the ND group. Thus, high fat diet mice represent insulin-resistant condition.
because these mice required 1.5-fold higher insulin to maintain normoglycemia. Figure 1 illustrates the blood glucose (Fig. 1A) and insulin (Fig. 1B) values at 0 (fasting) and 2 h after glucose challenge (5 g/kg p.o.). In the non-DB mice (ND), plasma glucose values returned to normal levels at 2 h after oral glucose challenge. However, DB mice exhibited higher fasting glucose (241 ± 32 mg/dl, indicated at 0-h time point in Fig. 1A) and glucose intolerance as indicated by high glucose levels at 2 h (450 ± 78 mg/dl; Fig. 1A). The insulin levels in the DB and non-DB (ND) were similar at both 0 and 2 h after glucose administration (Fig. 1B). On the other hand, the HFD mice, in spite of normal glucose levels at 2 h after glucose treatment, exhibited insulin resistance as evidenced by higher insulin levels (~3-fold) at 2 h after glucose administration (Fig. 1B) compared with the ND mice. Thus, the oral glucose tolerance test proved three points: 1) feeding high fat diet resulted in insulin resistance, 2) DB mice exhibited higher fasting glucose; and 3) glucose intolerance was evident in DB mice.

Resistance of Type 2 Diabetic Mice to Model Hepatotoxicants

Lethality Studies. Liver injury initiated by APAP (600 mg/kg i.p.) markedly progressed in the non-DB (ND, ND + STZ, and HFD) mice as indicated by 80% mortality in contrast with 80% survival of the DB mice (Table 1). Death occurred between 8 and 24 h after APAP administration. In addition, BB (0.5 ml/kg i.p.) and CCl₄ (1.25 ml/kg i.p.) toxicity was greater in non-DB mice, leading to 80 and 50% mortality in the non-DB groups compared with 80 and 70% survival of the DB mice, respectively (Table 1). The non-DB mice died between 48 and 96 h after BB or CCl₄ administration. No mortality occurred in the vehicle control DB and non-DB mice. These findings suggested that type 2 DB mice are resilient to drug and toxicant-induced hepatotoxicity. Resilience of DB mice to APAP toxicity was chosen for further mechanistic investigation.

Hepatotoxicity. Plasma ALT (Fig. 2A) and AST (Fig. 2B) in the non-DB mice (ND, ND + STZ, and HFD) exhibited significant increases, which correlated with the high mortality observed in this group between 8 to 24 h after APAP administration (600 mg/kg i.p.).

In the non-DB groups (ND, ND + STZ, and HFD), 20 mice per time point per group were used at the 12-, 24-, 48-, and 96-h time points to ensure survival of four mice at each time point. Plasma ALT activity increased in non-DB (ND, HFD, and ND + STZ) mice after APAP administration, peaked at 12-, 24-, 48-, and 96-h time points to allow survival of four mice for time-course studies.

Table 1

Effect of type 2 diabetes on toxicity of APAP, BB, and CCl₄ in male Swiss-Webster mice

<table>
<thead>
<tr>
<th>Treatment</th>
<th>ND</th>
<th>ND + STZ</th>
<th>HFD</th>
<th>HFD + STZ</th>
</tr>
</thead>
<tbody>
<tr>
<td>% mortality</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>APAP (600 mg/kg i.p.)</td>
<td>80</td>
<td>80</td>
<td>80</td>
<td>20</td>
</tr>
<tr>
<td>BB (0.5 ml/kg i.p.)</td>
<td>80</td>
<td>80</td>
<td>80</td>
<td>20</td>
</tr>
<tr>
<td>CCl₄ (1.25 ml/kg i.p.)</td>
<td>50</td>
<td>50</td>
<td>50</td>
<td>30</td>
</tr>
</tbody>
</table>

* All deaths occurred between 8 and 24 h after toxicant challenge.
# All deaths occurred between 48 and 72 h after toxicant challenge.

Fig. 1. Effect of type 2 diabetes on glucose and insulin in oral glucose intolerance test in male Swiss-Webster mice. Male SW mice were fed either normal diet or high fat diet for 2 months, and on day 60, they were injected with either STZ (120 mg/kg i.p. in citrate buffer, pH 4.3) or citrate buffer (10 ml/kg i.p.). Injecting STZ to high fat diet-fed mice (HFD + STZ) induced type 2 diabetes. On day 70, plasma glucose and insulin levels were estimated as mentioned under Materials and Methods. On day 71, DB and non-DB mice were administered glucose solution (20% glucose solution; 5 g/kg p.o.). Blood samples were collected under diethyl ether anesthesia at 0 and 2 h after glucose administration. Plasma glucose and insulin levels from these samples were estimated as described under Materials and Methods. *, significantly different from respective 0-h time point; †, significantly different from the non-DB normal diet-fed control-injected citrate buffer (ND) group at the same time point. p ≤ 0.05.

Fig. 2. Effect of type 2 diabetes on liver injury by APAP treatment in male Swiss-Webster mice. Plasma ALT (A) and AST (B) activities over a time course after APAP administration. Mice were made DB as described in Fig. 1. On day 71, DB and non-DB mice received APAP (600 mg/kg i.p. in warm basic saline, pH 8). Blood samples were collected under diethyl ether anesthesia at various time points (0–96 h) after APAP administration (n = 4/time point/group, with the exception of non-DB groups, n = 20 at 12-, 24-, 48-, and 96-h time points to allow survival of enough mice for time-course studies). *, significantly different from respective 0-h time point; †, significantly different from the non-DB normal diet-fed control-injected citrate buffer (ND) group at the same time point. p ≤ 0.05.
12 h, and was elevated up to 24 h (Fig. 2A), resulting in 80% mortality between 8 to 24 h. The persistence and progression of liver injury over the time course are concordant with the time of mortality observed in these groups (Table 1). In the surviving non-DB mice, the injury regressed to normal by 96 h. In contrast, DB mice exhibited substantially lower liver injury at 6 (~20-fold), 12 (~24-fold), and 24 h (~6-fold) compared with non-DB (ND) at the respective time points. In the DB mice, injury progressed up to 24 h compared with 0 h (resulting in 20% mortality between 8 to 24 h) and then regressed to normal levels by 96 h. No significant difference in the liver injury was evident at 96 h between the surviving DB and non-DB mice. Thus, even though the DB mice showed progressive liver injury up to 24 h after APAP administration, it was significantly low compared with the non-DB mice. Plasma AST also revealed a similar pattern of liver injury (Fig. 2B) as seen with plasma ALT in both the DB and non-DB groups. In DB and non-DB groups receiving half normal saline, ALT/AST were measured at 0 (data shown) and 6, 12, and 24 h after saline administration, and no liver injury was evident (data not shown).

**Histopathology.** For comparison of histopathology, calpain, calpastatin, and PCNA results, the ND group was selected as the representative non-DB control since the extent and pattern of APAP-induced injury at respective time points in all the three non-DB groups (ND, HFD, and ND + STZ) were the same. Liver sections stained with H&E were examined by light microscopy for multifocal necrosis, vaculization, and inflammatory cell infiltration. There was no difference in the non-DB (ND) (Fig. 3A) and DB (Fig. 3B) mice livers at 0 h. ND mice treated with APAP showed marked necrotic lesion in the liver as early as 6 h (Fig. 3C). Inflammatory cell infiltration was evident in the non-DB mice with mild-to-moderate coagulative necrosis at 6 h (Fig. 3C). Hepatocellular necrosis and vaculization spread toward the perportal area with time. These effects were progressive by 12 h, manifesting severe-to-maximal coagulative necrosis with extensive bridging of necrotic zone affecting all lobules at 12 h (Fig. 3E) compared with 0 h. From 24 h (Fig. 3G), the surviving non-DB mice showed regression of necrosis up to 48 h (data not shown), and there was no evidence of necrosis by 96 h (data not shown). On the other hand, DB mice treated with the same dose of APAP showed minimal necrosis and histological damage at 6 h (Fig. 3D) and 12 h (Fig. 3F) and regression of necrosis was evident as early as 24 h (Fig. 3H).

**APAP Bioactivation, Toxicokinetics, and Hepatic Glutathione in Diabetic Mice**

For comparison of bioactivation-based mechanisms and the tissue repair response, the ND group was selected as the representative non-DB control.

**Effect of Diabetes on Hepatic CYP2E1.** Western blot analysis revealed that hepatic microsomal CYP2E1 protein in the DB mice was not different from that in the non-DB mice (ND and HFD) (Fig. 4, A and B). Microsomal CYP2E1 enzyme activity (Fig. 4C) measured as p-nitrophenol hydroxylation was also unchanged in the DB mice relative to non-DB mice (ND), confirming that neither hepatic microsomal CYP2E1 protein nor the enzyme activity is changed in the type 2 DB mice. However, in the HFD group (non-DB), the CYP2E1 enzyme activity was significantly lower compared with that in the ND (non-DB) group, in the absence of any change in CYP2E1 protein.

**Covalent Binding.** Total covalent binding of [14C]APAP was estimated as a measure of reactive intermediate production. Covalent binding sharply increases from 30 min and reaches a peak by 2 h in male SW mice (Shankar et al., 2003a). No difference was found in covalent binding of [14C]APAP-derived radiolabel to liver macromolecules between non-DB (ND; 2.1 ± 0.4 dpm × 10^12/mg protein) and DB mice (2.3 ± 0.6 dpm × 10^12/mg protein) at 2 h after APAP administration. These data suggest that bioactivation of APAP is similar in both non-DB and DB mice.

**APAP Toxicokinetics.** Plasma levels of APAP did not differ between the non-DB (ND) and DB mice (Fig. 5A). Plasma t_{1/2} of APAP in DB (78 ± 22 min) was the same as in non-DB (ND; 70 ± 18 min) mice. The cumulative percentage of total APAP dose excreted in the urine by 12 and 24 h after APAP administration as APAP in the non-DB (ND; 2.9 ± 0.1 and 5.8 ± 0.9, respectively) and DB mice (2.6 ± 0.04 and 5.7 ± 1.2, respectively) was not significantly different. Thus,
plasma and urinary APAP concentrations and the plasma APAP $t_{1/2}$ were the same in the non-DB (ND) and DB mice, indicating that altered toxicokinetics of APAP is unlikely to be the reason for protection observed in the DB mice from APAP hepatotoxicity. However, the plasma levels of APAP-G, a nontoxic metabolite of APAP, was significantly lower (~32%) in the DB mice compared with non-DB (ND) mice (Fig. 5B). APAP-G represents 70 to 80% of APAP metabolism in the male SW mice (Hazelton et al., 1986; Shankar et al., 2003a). The cumulative percentage of total APAP dose excreted as APAP-G by the non-DB (ND) mice in urine by 12 and 24 h after APAP administration was 20.3 ± 0.3 and 78.8 ± 0.4, respectively, and in the DB mice it was 63.8 ± 2.1 and 80.8 ± 1.6, respectively. At 12 h after APAP administration, urinary elimination of APAP-G was ~31% higher in the DB mice, consistent with polyurea and lower plasma levels of APAP-G in this group compared with non-DB (ND) mice. However, by 24 h the cumulative percentage of total APAP dose eliminated as APAP-G in both the groups was the same, indicating that there was no difference in the detoxification of APAP by glucuronidation between the two groups.

**Hepatic Glutathione.** Hepatic glutathione was unaffected by diabetes (Fig. 6). Regardless of DB condition, there was a dramatic depletion of total as well as reduced glutathione at 2 h after APAP administration. Whereas glutathione depletion was persistent in non-DB mice at 6 h after APAP treatment, that in the DB mice was largely restored to normal by 6 h (Fig. 6). In the non-DB mice, glutathione depletion was sustained, consistent with higher liver injury observed at 6 h compared with the DB mice.

**Progression/Regression of Injury**

**Calpain Immunohistochemistry.** In the present study, calpain leakage was investigated in the livers of DB and non-DB mice after APAP treatment. Brown color indicated calpain-positive staining (Fig. 7). Minimal calpain staining was found in the DB and non-DB mice at 0 h (Fig. 7, A and B). Notable calpain staining was primarily found in the necrotic area at 6 h (Fig. 7C) in the ND mice after APAP treatment that progressively increased, resulting in intense staining at 12 h that was sustained at 24 h (Fig. 7, E and G), indicating calpain-mediated progression of liver injury. Starting at 48 h in the surviving ND mice, there was decreased calpain leakage as evidenced by decrease in calpain staining, injury regressed, and complete recovery was evident at 96 h (data not shown). In contrast, the intensity and extent of calpain staining was very low over the entire time course after APAP treatment.
administration in the DB mice compared with ND mice. At 6 h after APAP administration, calpain leakage was very low in the DB mice (Fig. 7D) compared with ND mice. This observation was consistent with the liver injury, which is significantly lower in the DB mice compared with the ND mice at the same time point. Moreover, during the onward time course up to 24 h, calpain leakage was substantially lower in the DB mice (Fig. 7, F and H). At 48 h (data not shown), minimal calpain staining consistent with complete recovery was evident in the DB mice. These data indicate that the extent of calpain release governs the degree of progression of injury.

### Tissue Repair

The objective of this study was to investigate whether in type 2 diabetes higher numbers of cells advance to S phase of cell division, giving the advantages of resistance against progression of injury and early onset of tissue repair upon toxic challenge. S phase DNA synthesis was investigated in the DB and non-DB mice by $[^{3}H]$T pulse labeling and by counting the number of cells in S phase identified by PCNA immunohistochemistry (Fig. 8).

**$[^{3}H]$T Pulse-Labeling Study.** Stimulation of the S phase of cell division cycle is an obligatory step in cell division and tissue repair. S phase DNA synthesis was measured by $[^{3}H]$T pulse labeling (Fig. 8A) in the non-DB (ND) and DB livers. The $[^{3}H]$T pulse-labeling study revealed that DNA synthesis was increased (2-fold) in DB mice compared with the non-DB mice, indicating that the S phase DNA synthesis is significantly enhanced due to type 2 DB in SW mice.

**PCNA Assay.** Immunohistochemical staining of PCNA (Fig. 8) was conducted to identify and count the cells in S phase of cell division cycle in the non-DB (ND) and DB mice and to verify the findings of $[^{3}H]$T pulse-labeling study. In the non-DB (ND) mouse livers at 0 h, 95% of the hepatocytes were found in the G0 phase (Fig. 8B), with only 1% of the hepatocytes in S phase of cell cycle. After APAP treatment, a minimum number of cells progressed to S phase of cell cycle at 6 and 12 h (data not shown). Cell-cycle progression was suppressed and delayed in ND mice, and only in the surviving APAP-treated mice was there any evidence of successful cell-cycle progression. In the surviving ND mice, at 24 h a significant number of cells entered S phase, progressing to G2 and M phases by 96 h (data not shown). In contrast, in DB mice, an 8-fold higher number of cells had advanced to S phase compared with that of non-DB mice, confirming much higher number of S phase cells in normally quiescent liver of these mice (Fig. 8, C and D). PCNA analysis revealed 3- and 5-fold increase in the number of cells in S phase at 12 and 24 h, respectively, after APAP administration in the DB mice compared with ND mice (data not shown). The results from PCNA analysis were consistent with the results of $[^{3}H]$T pulse-labeling studies, confirming higher number of S phase cells in the DB mice at 0 h compared with ND mice.

Thus, after APAP treatment, inhibited cell-cycle progression in ND mice leads to progression of liver injury and mortality, whereas in the DB mice, diabetes-related advancement of hepatocytes to S phase enabled the mice to inhibit progression of injury, and stimulated cell-cycle progression resulted in regression of injury, restoration of liver function, and complete recovery.

**Calpastatin Immunohistochemistry**

Calpastatin expression was investigated in the non-DB and DB mice with and without APAP treatment. Brown color indicated calpastatin-positive staining (Fig. 9). Minimal level of calpastatin staining was seen in the ND (non-DB) mice at 0, 6, and 12 h (Fig. 9, A, C, and E), consistent with lower number of S phase cells in the ND mice after APAP treatment. However, in the surviving ND mice, calpastatin staining was evident in the dividing/newly divided cells in the perinecrotic areas at 24 h (Fig. 9G) and 96 h (data not shown). A remarkable level of calpastatin staining was found in the DB mice at 0 h (Fig. 9B) consistent with the higher number of S phase cells in the DB mice, thereby indicating that cells in S phase overexpress calpastatin. After APAP administration (6–24 h), calpastatin expression was observed in larger areas of the lobule at 6 and 12 h (Fig. 9, D and F) and was distributed over almost the entire lobule at 24 h (Fig. 9H) in the DB mice compared with ND mice (Fig. 9, C, E, and G). This observation is consistent with the greater number of cells entering and progressing in the cell division cycle in the

---

**Fig. 7.** Effect of type 2 diabetes on calpain leakage after APAP-induced liver injury in male SW mice. Typical photomicrographs of liver sections from non-DB mice (ND) (right) and DB mice (HFD + STZ) (left) at 0, 6, 12, and 24 h after APAP administration. A, C, E, and G, non-DB (ND) mice 0, 6, 12, and 24 h post-treatment with APAP. B, D, F, and H, DB mice 0, 6, 12, and 24 h post-treatment with APAP. c, central vein; brown color indicates calpain-positive staining shown by arrows. Original magnification, 100×.
DB mice than in the ND mice. Overexpression of calpastatin in the dividing/newly divided cells in the DB mice after APAP administration is consistent with the regression or lower progression of liver injury observed in the DB mice. These data indicate that the extent of calpastatin staining governs the calpain-mediated progression of injury.

**CYP4A Expression.** Resiliency of type 1 DB mice to APAP-induced hepatotoxicity is dependent on PPAR-α-mediated enhancement of liver tissue repair (Shankar et al., 2003b). The objective of this experiment was to investigate whether higher tissue repair in type 2 DB mice is mediated via PPAR-α activation. Western blot analysis revealed no difference in CYP4A expression between the non-DB and DB mice livers. These results indicate that the increased tissue repair in type 2 diabetes is not mediated via PPAR-α activation, unlike in type 1 DB mice.

**Antimitotic Intervention**

This experiment was conducted to examine whether advancement of liver cells through cell division cycle in DB mice even before APAP administration is critical in preventing progression of liver injury initiated by bioactivation of APAP. First, lethality studies were conducted with and without CLC intervention as a test of the concept. Second, time-course studies were conducted to measure liver injury as assessed by plasma transaminases. Third, covalent binding of [14C]APAP-derived radiolabel to liver tissue was examined as a measure of APAP bioactivation with and without CLC intervention.

**Lethality Study after CLC Intervention.** DB mice pretreated with CLC 48 (2 mg/kg i.p.) and 12 h (1.5 mg/kg i.p.) before APAP administration exhibited inhibition of 8-fold increase in the number of S phase cells in type 2 DB mice as estimated by PCNA immunohistochemistry (data not shown). APAP-induced mortality was 70% in the CLC-intervened DB mice (Table 2). Eighty percent of the DB mice not intervened with CLC but receiving the same dose of APAP (600 mg/kg i.p.) survived, suggesting a pivotal role of diabetes-related advancement of cells to S phase in the DB-induced resistance (Table 2). Deaths in ND mice and CLC-intervened DB mice receiving APAP occurred during the same time frame (8–24 h; Tables 1 and 2), suggesting that protective mechanism of DB was abolished by CLC intervention. DB DW and ND mice treated with CLC + saline alone did not show any signs of toxicity. These results underscore the critical importance of cell division and tissue repair in imparting a survival advantage to the DB mice challenged with a lethal dose of APAP.

**Hepatotoxicity after CLC Intervention.** If liver cells advancing to S phase and other phases of cell division is
critical for hepatoprotection by preventing the progression of injury, CLC intervention before APAP exposure should lead to two effects in the DB mice. First, initial injury of APAP should not change. Second, initiated liver injury should expand by progression because the resistance, which would have come with cells advancing in cell division cycle, is lacking. To examine these effects, a time course (0–24 h) study was conducted. Plasma ALT and AST (Fig. 10, A and B) elevations in the CLC-intervened DB mice (DB + CLC) at 2 h after APAP administration were not different from those of non-DB mice (ND) (right) and DB mice (HFD + STZ) (left) at 0, 6, 12, and 24 h after APAP administration. A, C, E, and G, non-DB (ND) mice 0, 6, 12, and 24 h post-treatment with APAP. B, D, F, and H, DB mice 0, 6, 12, and 24 h post-treatment with APAP. c, central vein. Brown color indicates calpastatin-positive staining shown by arrows. Original magnification, 200×.

Table 2

<table>
<thead>
<tr>
<th>Treatment Groups</th>
<th>Dose of APAP</th>
<th>Total No. of Mice</th>
<th>Mortality of Deaths</th>
<th>% Survival</th>
</tr>
</thead>
<tbody>
<tr>
<td>DB mice + DW + APAP</td>
<td>600 mg/kg</td>
<td>10</td>
<td>2*</td>
<td>80</td>
</tr>
<tr>
<td>DB mice + CLC + APAP</td>
<td>600 mg/kg</td>
<td>10</td>
<td>7*</td>
<td>30</td>
</tr>
<tr>
<td>DB mice + CLC + saline</td>
<td>10 mg/kg</td>
<td>10</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Non-DB (ND) mice + CLC + saline</td>
<td>10 mg/kg</td>
<td>10</td>
<td>0</td>
<td>0</td>
</tr>
</tbody>
</table>

*All deaths occurred between 8 and 24 h after toxicant challenge.

Fig. 9. Effect of type 2 diabetes on calpastatin expression after APAP treatment in male SW mice. Typical photomicrographs of liver sections from non-DB mice (ND) (right) and DB mice (HFD + STZ) (left) at 0, 6, 12, and 24 h after APAP administration. A, C, E, and G, non-DB (ND) mice 0, 6, 12, and 24 h post-treatment with APAP. B, D, F, and H, DB mice 0, 6, 12, and 24 h post-treatment with APAP. c, central vein. Brown color indicates calpastatin-positive staining shown by arrows. Original magnification, 200×.

Fig. 10. Effect of type 2 diabetes on liver injury by APAP treatment in male SW mice after CLC intervention. Plasma ALT (A) and AST (B) activities over a time course after APAP administration. Mice were made DB as described in Fig. 1. After confirming type 2 diabetes on day 68 and on days 69 and 70, one group of DB mice (DB + CLC; n = 4/time point for 0 and 6 h and n = 15/time point for 12 and 24 h) was treated with two doses of CLC (2 mg/kg i.p. in distilled water at 48 h and 1.5 mg/kg i.p. in distilled water at 12 h, respectively) before APAP treatment. The other group of DB mice (DB + DW) received distilled water (10 ml/kg i.p.; n = 4/time point/group except for ND and DB groups, n = 15 at 12- and 24-h time points to allow survival of enough mice for time-course studies). #, significantly different from respective 0-h time point. !, significantly different from the non-DB normal diet-fed control-injected citrate buffer (ND) group at the same time point. *p ≤ 0.05.

Male SW mice were fed either high fat diet or normal diet. On day 60, male SW mice were injected with either STZ (120 mg/kg i.p. in citrate buffer, pH 4.3) or citrate buffer (10 ml/kg i.p.). On day 68, type 2 diabetes was confirmed by measuring plasma glucose and insulin levels. On days 69 and 70, the DB (DB + CLC) and non-DB (ND) mice received CLC at 2 and 1.5 mg/kg i.p. in distilled water at 48 and 12 h before APAP administration, respectively, whereas the other group of DB mice received distilled water (DB + DW; 10 ml/kg i.p. at 48 and 12 h before APAP treatment). On day 71, the groups DB (DB + CLC and DB + DW) were injected with a single dose of APAP (600 mg/kg i.p. in warm basic saline, pH 8). In addition, another group of DB and non-DB (ND) mice treated with CLC to control for any effects of CLC itself received half-normal saline (vehicle for APAP). Survival and mortality were observed three times on the 1st day and twice daily thereafter for a total of 14 days. Number of deaths and time were recorded.
activity increased after APAP administration, peaked at 12 h, and was elevated until 24 h (Fig. 10A) as observed in Fig. 2, resulting in 80% mortality between 8 to 24 h. The liver injury in the DB + CLC mice was not significantly different from that in the ND group at 6, 12, and 24 h. Plasma AST also revealed a similar pattern of liver injury (Fig. 10B) as seen with plasma ALT in the DB + DW, DB + CLC, and ND groups. These results indicate that expansion of initiated injury destroys the liver in ND and CLC-intervened DB mice receiving APAP. Conversely, it is lack of expansion or progression of injury initiated by APAP that protects the DB mice.

**Covalent Binding after CLC Intervention.** No difference was found in covalent binding of [14C]APAP-derived radiolabel to liver macromolecules between non-DB (ND; 2.1 ± 0.4 dpm × 10^9/mg protein), CLC-unintervened DB mice (DB + DW; 2.3 ± 0.6 dpm × 10^9/mg protein), and CLC-intervened DB mice (DB + CLC; 2 ± 0.3 dpm × 10^9/mg protein) at 2 h after APAP administration. These data suggest that CLC intervention did not alter the covalent binding of [14C]APAP-derived radiolabel to liver macromolecules compared with the unintervened DB mice (DB + DW).

**Discussion**

DB patients have nearly 2-fold higher risk of acute liver failure, chronic liver failure, and hepatocarcinogenesis compared with non-DB patients (El-Serag and Everhart, 2002; El-Serag et al., 2004). Several studies in DB rats indicate that both type 1 and type 2 diabetes are predisposing factors for hepatic sensitivity to drugs and toxicants (El-Hawari and Plaa, 1983; Grant and Duthie, 1988; Watkins et al., 1988; Wang et al., 2000a; Sawant et al., 2004). However, marked species difference in hepatoxic sensitivity exists between type 1 DB rats and mice (Shankar et al., 2003a; Wang et al., 2000a). Type 1 DB rats are sensitive to TA-induced hepatotoxicity because of compromised liver tissue repair (Wang et al., 2000a). In contrast, type 1 DB mice are resistant to several hepatotoxicants. Studies after APAP treatment (600 mg/kg i.p.) revealed that protection in the type 1 DB mice is pre-dominantly because of increased PPAR-α-dependent compensatory tissue repair, which prevents APAP-initiated liver injury from progressing (Shankar et al., 2003a,b). Surprisingly, very few studies have investigated the effect of type 2 diabetes on sensitivity of hepatotoxicants, even though it is the most prevalent form of diabetes, representing 90 to 95% of the DB population. Sawant et al. (2004) reported for the first time that the type 2 DB rats are sensitive to hepatotoxicity of several model hepatotoxicants, including CCl₄. Mechanistic studies revealed that the increased sensitivity to CCl₄ and TA hepatotoxicity is due to inhibited compensatory tissue repair, which prevents APAP-initiated liver injury from progressing (Shankar et al., 2003a,b).

Surprisingly, very few studies have investigated the effect of type 2 diabetes on sensitivity of hepatotoxicants, even though it is the most prevalent form of diabetes, representing 90 to 95% of the DB population. Sawant et al. (2004) reported for the first time that the type 2 DB rats are sensitive to hepatotoxicity of several model hepatotoxicants, including CCl₄. Mechanistic studies revealed that the increased sensitivity to CCl₄ and TA hepatotoxicity is due to inhibited compensatory tissue repair, which prevents APAP-initiated liver injury from progressing (Shankar et al., 2003a,b).

In stark contrast to our findings in type 2 DB rats, lethality studies revealed that type 2 DB mice are protected from hepatotoxicity and mortality induced by model hepatotoxicants such as CCl₄, BB, and APAP, indicating a marked species difference in the sensitivity of type 2 diabetes to drug- and toxicant-induced hepatotoxicity. Using APAP as a model hepatotoxicant, mechanisms of protection in type 2 DB mice were investigated. Time-course studies of liver injury revealed that even though liver injury was same at 2 h, progression of liver injury was dramatically lower in the DB mice compared with the non-DB mice. Although this may be explained by several potential mechanisms, for this study the following four leading mechanisms were investigated: 1) decreased bioactivation of APAP, 2) increased detoxification via glucuronidation and glutathione conjugation of APAP, 3) advancement of hepatocytes in cell division cycle in the type 2 DB mice favorably influencing liver tissue repair after APAP administration, and 4) progression of APAP-initiated liver injury is prevented because calpain is inhibited by overexpression of calpastatin in dividing/newly divided cells. First and foremost, decreased bioactivation of APAP because of lower hepatomicrosomal CYP2E1 expression and activity and lower [14C]APAP covalent binding were investigated. In the type 2 DB mice, CYP2E1 protein, its enzyme activity (Fig. 4, B and C), and covalent binding of [14C]APAP-derived radiolabel to liver macromolecules was not different compared with non-DB mice, indicating that the initial bioactivation-based liver injury is the same in DB and non-DB mice. Our present findings in the DB mice are consistent with the unaltered CYP2E1 in type 2 DB rats. In the high fat diet-based type 2 DB rats, neither the CYP2E1 protein nor activity was altered (Sawant et al., 2004) compared with non-DB rats. Our previous findings in type 2 DB rats and present findings in the mice are consistent with the unchanged CYP2E1 protein and mRNA in type 2 DB ob/ob mice and Zucker rats (Novak and Woodcroft, 2000). Thus, in these rodent models of type 2 diabetes, the emerging picture indicates that liver microsomal CYP2E1 does not change significantly. In contrast, in type 1 DB, a different and divergent picture is emerging. In STZ-induced type 1 DB rats, liver microsomal CYP2E1 protein and enzyme activity are markedly increased (Wang et al., 2000b), whereas in type 1 DB mice a small, but significant (30%) decrease occurs (Shankar et al., 2003a). Sakuma et al. (2001) have also reported a similar species difference in the modulation of hepatic CYP2E1 between STZ-induced type 1 DB rats and mice. In type 2 DB patients, contradictory evidence of increased CYP2E1 (Wang et al., 2003) and unchanged CYP2E1 protein and activity (Lucas et al., 1998) have been reported.

The second potential mechanism is increased glucuronidation and glutathione conjugation of APAP in the type 2 DB mice. Diabetes is associated with increased water intake, altered kidney architecture and kidney function (Shankar et al., 2003a), and consequently 10-fold higher urine output. Thus, it is reasonable to expect that type 2 diabetes may alter toxicokinetics of APAP. However, our studies revealed no difference between non-DB (ND) and DB mice in plasma APAP levels, plasma APAP t_{1/2}, and the urinary excretion of APAP. In the SW mice used in the current study APAP-G conjugate represents 70 to 80%, whereas APAP-sulfate represents 5 to 7% of APAP metabolism (Hazelton et al., 1986; Shankar et al., 2003a). Therefore, a significant change in the detoxification of APAP by glucuronidation in the type 2 DB...
mice may be expected to impact initiation of APAP-induced liver injury. Plasma APAP-G levels were 32% lower consistent with 31% increased urinary excretion of APAP-G in the type 2 DB mice compared with ND mice at 12 h after APAP treatment. However, by 24 h the cumulative percentage of APAP dose excreted as APAP-G was same in both the groups, obviating increased detoxification of APAP by glucuronidation as a mechanism of protection in DB mice. It is clear that the lower plasma levels of APAP-G in DB mice is a reflection of more rapid excretion of this metabolite in urine as a result of polyurea associated with diabetes.

Higher liver GSH content is a very important indicator of whether detoxification of reactive metabolite of APAP is higher in DB mice and whether it affords greater hepatoprotection as an antioxidant in the DB mice. Glutathione levels at the initial time points when the injury begins are critical for the hepatoprotective action, whereas at later time points when the injury has progressed drastically, glutathione levels may be affected because of the extent of injury. The present study indicated that type 2 diabetes does not change GSH status of the liver (Fig. 6). Depletion of hepatic glutathione was same in the DB and non-DB mice at 2 h after APAP administration, whereas higher glutathione levels in the DB mice at 6 h compared with non-DB mice may be a consequence of 20-fold lower injury in the DB mice compared with non-DB mice, indicating that increased glutathione conjugation may not be the underlying mechanism of protection observed in the DB mice from APAP hepatotoxicity. Thus, no change in hepatic CYP2E1 protein and enzyme activity, lack of difference in covalent binding of [14C]APAP-derived radiolabel to liver macromolecules, and lack of significant difference in hepatic glutathione levels between the DB and non-DB mice collectively suggest that decreased bioactivation and increased detoxification are unlikely to explain diabetes-induced protection from APAP hepatotoxicity.

The third potential mechanism for protection from progression of APAP-initiated liver injury in the type 2 DB mice is advancement of hepatocytes in cell division cycle that may confer resistance against progression of APAP-initiated injury and favor a higher tissue repair response after APAP administration. The present study revealed that type 2 DB mice have 8-fold higher number of cells in S phase of the cell division cycle compared with non-DB mice, indicating that advancement of cells in cell division cycle in the DB mice results in protection from progression of APAP-initiated liver injury. To address the question of whether increased advancement of hepatocytes in cell division cycle in type 2 DB mice is indeed the critical event, CLC antimitotic intervention study was conducted. CLC intervention 48 and 12 h before APAP treatment abolished the protection by diabetes, resulting in 70% mortality in the CLC-intervened DB mice (DB + CLC) receiving APAP compared with 20% mortality in the CLC-unintervened DB mice (DB + DW) receiving the same dose of APAP. CLC intervention inhibited the diabetes-associated advancement of cells in the cell division cycle, and the initial liver injury of APAP was same in CLC intervened (DB + CLC) and unintervened DB mice (DB + DW) mice. However, APAP-initiated liver injury progressed, culminating in liver failure and death only in the CLC-intervened DB mice challenged with APAP. To rule out the possibility that CLC intervention may have affected APAP bioactivation, covalent binding of [14C]APAP-derived radiolabel to liver tissue was measured. Lack of any difference in covalent binding of [14C]APAP-derived radiolabel to liver macromolecules and the identical initial liver injury in the DB + CLC and DB + DW groups of mice indicates that CLC pretreatment does not alter the initial bioactivation-based injury. Thus, inhibition of higher number of S-phase cells or tissue repair in the CLC-intervened DB mice results in progression of APAP-initiated liver injury. Our results are consistent with several studies that have reported the importance of robust compensatory tissue repair response in determining the final outcome of toxicity (Mangipudy et al., 1995; Ramaiah et al., 1998; Soni et al., 1999; Wang et al., 2001; Mehendale, 2005). Furthermore, inhibition of cell division via antimitotic intervention with CLC has been shown to result in progression of injury from nonlethal doses of TA (Mangipudy et al., 1996), CCl4 (Rao and Mehendale, 1993), and APAP (Shankar et al., 2003a). Thus, the markedly lower progression of APAP-initiated liver injury in type 2 DB mice is because of increased advancement of cells in the cell division cycle.

Another important finding from our study is lower calpain leakage and lower progression of APAP-initiated injury in the DB mice compared with greater calpain-mediated progression of injury in the non-DB mice. Limaye et al. (2003) have shown that leakage of calpain, a hydrolytic enzyme, from the dying hepatocytes causes progression of injury following APAP-induced necrosis in mice and after CCl4-induced necrosis in rats. Calpain inhibition either by overexpression of calpastatin (Limaye et al., 2005; Mehendale and Limaye, 2005), an endogenous inhibitor of calpain, in dividing/newly divided cells or by administration of a synthetic inhibitor of calpain results in regression of APAP-initiated injury (Limaye et al., 2003). Therefore, the fourth potential mechanism we investigated is whether increasing leakage of calpain in the intercellular space in the livers of APAP treated ND mice is in concordance with the progression of APAP-initiated injury and whether calpastatin overexpression is commensurate with the remarkably inhibited progression of injury in the DB mice after APAP administration. First, in the APAP-treated ND mice there was evidence of progressively increasing leakage of calpain in the intercellular space concordant with the progression of liver injury and death in mice. Only in the surviving 20% of the mice did the appearance of intercellular calpain decline. In the DB mice receiving APAP, although initially calpain did occur in the intercellular space, the overexpression of calpastatin incapacitated the degradative action of intercellular calpain. Calpastatin was overexpressed in DB mice owing to the advancement of hepatocytes to S phase. In contrast, in the ND mice, lack of such advancement of hepatocytes to S phase and hence lack of calpastatin expression allowed APAP-initiated liver injury to progress through calpain-mediation. Therefore, these findings are consistent with inhibited progression of APAP-initiated injury by overexpressed calpastatin in the DB mice.

Why do cells advance in cell division cycle in the DB mice? In the type 1 DB mice, resiliency of type 1 DB mice to APAP-initiated liver injury is dependent on PPAR-α-mediated higher liver repair (Shankar et al., 2003b). Therefore, whether PPAR-α is activated in livers of type 2 DB mice was investigated in the present study. CYP4A expression, a marker of PPAR-α activation, was not different in type 2 DB mice compared with non-DB (ND) mice, suggesting that the
higher tissue repair in type 2 DB mice is independent of PPAR-α activation. Studies to understand mechanisms of higher advancement of cells in cell division cycle in the DB mice are worthy of further investigations.

In conclusion, four significant aspects of the present study are as follows. First, in addition to the previously established resistance of type 1 DB mice to hepatotoxicans, the findings of this study indicate that type 2 DB mice are also resistant to hepatotoxic drugs and toxicants. Second, a significant number of normally quiescent hepatocytes of the adult mice advance to S phase of cell division in type 2 diabetes, making these cells resistant to the destructive action of calpain on the one hand and favoring promptly stimulated robust compensatory liver tissue repair upon exposure to APAP on the other hand. Third, overexpression of calpastatin in dividing/newly divided cells inhibits the destructive actions of calpain, preventing the progression of APAP-initiated liver injury. Fourth, marked species differences in hepatotoxic sensitivity between DB mice and DB rats and similarity of DB rats and DB patients to hepatotoxic sensitivity suggest that the type 2 DB rat model may be representative of DB patients and could be used for testing hepatotoxic sensitivity.

References


